Near East University Initiates Patent Process for a “Drug Candidate” Developed Against “Candida auris”, a Major Source of Hospital-Acquired Infections!
Date Added: 17 November 2026, 14:56

Near East University researchers have filed a patent application for a “drug candidate” molecule developed to combat “Candida auris”(Candidozyma auris), a fungus responsible for hospital-acquired infections, particularly in intensive care units. Following the successful completion of “in vitro” experiments, the goal is to further develop this molecule through clinical trials and eventually make it available for medical use. Efforts are also underway to develop the molecule into various forms, including disinfectants, creams, and tablets.

A significant milestone has been reached in Near East University’s research on “Candida auris”, a fungus that complicates the fight against infections due to its multi-drug resistance and ability to persist in hospital environments. A patent application has been filed for a molecule developed by Near East University researchers, which has demonstrated effectiveness against this fungus in laboratory tests. The evaluation process for this “drug candidate” is currently ongoing.

Following the successful completion of “in vitro” experiments, conducted in laboratory settings outside of a living organism, the research is set to advance to the next stages. The molecule, which has the potential to be developed into disinfectants, creams, and tablets, is intended for use in the healthcare sector, pending the completion of necessary research and regulatory approval processes tailored to its specific intended application.

From studying resistance traits to developing a new molecule

Prior to this patent application, researchers from Near East University, Gazi University, and Van Yüzüncü Yıl University conducted a comprehensive study examining the genetic and biological characteristics of “Candida auris” strains found in Turkey. Within the scope of the project, “Candida auris” strains collected from various centers across Turkey were analyzed. The research team included Prof. Dr. Tamer Şanlıdağ, Assoc. Prof. Dr. Faika Başoğlu, and Assoc. Prof. Dr. Ayşe Seyer from Near East University, alongside Prof. Dr. Ayşe Kalkancı and Dr. Burak Kuzu from other institutions in Turkey.

The study revealed that all the examined strains were resistant to fluconazole, an antifungal medication, and that 95% of them possessed a strong capacity to form biofilms. Furthermore, the varying levels of susceptibility to the four biocidal agents tested highlighted the need for new approaches, both in terms of clinical treatment and the decontamination of hospital environments.

The findings from this project, led by Assoc. Prof. Dr. Ayşe Seyer from the Near East University Experimental Health Sciences Research Institute, have helped guide further research into alternative molecules.

Its persistence in hospital environments complicates control efforts.

“Candida auris”, classified by the World Health Organization as a “critical priority pathogen”, can cause severe infections, particularly in intensive care units and among patients with weakened immune systems. In addition to its multidrug resistance, its ability to remain viable on surfaces for extended periods makes it difficult to control its spread within hospitals.

The biofilm layer formed by the fungus facilitates its attachment to surfaces such as catheters, medical devices, and respiratory or feeding tubes. Consequently, combating infections requires not only the treatment of patients but also the effective decontamination of hospital surfaces and equipment. Evaluating the developed molecule through various modes of application aims to create new options for treatment and infection control.

Experiments for the development of the drug candidate will continue.

Following successful results from in vitro experiments, further testing of the drug candidate is planned. The clinical trials required to bring the molecule to market as a medication are intended to be conducted either with the support of the Health Institutes of Turkey (TÜSEB) or through collaborations with pharmaceutical companies. These studies will evaluate the safety and efficacy of the drug candidate in humans. Efforts to develop the molecule into forms such as disinfectants, creams, and tablets will proceed in alignment with the intended use of each product. While a patent application has been filed to protect the intellectual property of the molecule, research will continue to transform laboratory findings into practical healthcare solutions.

Prof. Dr. İrfan Suat Günsel said: “We place great importance on transforming our scientific expertise into products that address the needs of society. The fact that the molecule developed by our researchers has reached the patenting stage is a valuable outcome of this approach.”

Prof. Dr. İrfan Suat Günsel, Chairman of the Board of Trustees of Near East University, emphasized that filing a patent application for the developed molecule marks a significant step toward transforming knowledge generated at the university into a tangible healthcare solution. “The research responsibility of universities extends beyond merely reaching scientific findings and it also encompasses creating the necessary conditions for these findings to be utilized for the benefit of society. As Near East University, we prioritize converting our scientific expertise into products that address societal needs. The fact that the molecule developed by our researchers has reached the patenting stage is a valuable outcome of this approach.”, he said.

Noting that drug development efforts require a robust research infrastructure, continuity, and inter-institutional collaboration, Prof. Dr. Günsel added, “There are still stages to be completed before the results obtained in the laboratory can be transformed into safe and effective products. We will continue to support our researchers throughout this process and strengthen collaborations that will contribute to the advancement of clinical trials and product development efforts. I congratulate all the scientists who have contributed to this work.”

Prof. Dr. Tamer Şanlıdağ: “In the next phase, we will examine the potential for developing this molecule into disinfectants, creams, or tablets, in accordance with the scientific criteria required for each specific area of application.”

Prof. Dr. Tamer Şanlıdağ, Rector of Near East University, who is also a member of the research team, noted that “Candida auris” is a pathogen that must be addressed from multiple perspectives, given both the resistance encountered during treatment and its persistence within hospital environments. “The strong biofilm formation and antifungal resistance we observed in the strains we studied underscore the importance of our efforts to develop alternative molecules. The fact that the molecule developed by our researchers has demonstrated efficacy in in vitro experiments is a significant finding. We will now proceed to evaluate this laboratory-observed efficacy in the subsequent stages of our research.” he said.

Emphasizing that scientific work will continue following the patent application, Prof. Dr. Şanlıdağ added, “Demonstrating the efficacy of a molecule in a laboratory setting is a crucial step in the drug development process. Before it can be used in humans, its safety and efficacy must be assessed through clinical trials. We aim to advance this process by establishing new collaborations. We will examine the potential for developing this molecule into disinfectants, creams, or tablets, in accordance with the scientific criteria required for each specific application.”